A Novel Laboratory Assay to Monitor Unfractionated Heparin Dosing in Patients Taking Apixaban Prior to Hospital Admission.

J Appl Lab Med 2020 Sep 30. Epub 2020 Sep 30.

Department of Pathology, University of Virginia Health System, Charlottesville, VA.

Introduction: When monitoring heparin, anti-Xa assays are susceptible to interference from apixaban taken before admission and can result in inappropriate dose adjustments that can negatively affect patient care.

Methods: We derived a novel assay, termed corrected heparin (CH), using quantified values from a chromogenic anti-Xa assay with heparin calibrators before and after heparinase treatment to eliminate any interference from apixaban within the patient sample. We retrospectively assessed 469 specimens from 72 patients at our institution who had their unfractionated heparin infusion monitored using the CH assay because of known apixaban use. These patients were included in the study if they had detectable apixaban levels (>0.1 IU/mL by anti-Xa).

Results: The analytical performance of the assay was evaluated, and precision was found to be 8.8% within 1 day and 13.3% over multiple days, with acceptable linearity (R2 = 0.997). Evaluation of clinical performance was compared with the partial thromboplastin time (PTT), showing a lack of correlation similar to comparisons between the PTT and anti-Xa assay (Blood Coagul Fibrinolysis 1993;4:635-8). The mean time to a therapeutic result in this cohort was 10 hours and 10 minutes. The CH assay was used to determine how long the apixaban was detected by the anti-Xa assay. The majority of patients (80%) still had measurable anti-Xa assay interference from apixaban at 24 hours after the last apixaban dose.

Conclusions: We have developed and evaluated an assay capable of quantifying heparin in the presence of apixaban. This assay showed acceptable performance in both analytical and clinical performance.

Download full-text PDF

http://dx.doi.org/10.1093/jalm/jfaa084DOI Listing
September 2020

Publication Analysis

Top Keywords

anti-xa assay
interference apixaban
clinical performance
unfractionated heparin
apixaban patients
heparin infusion
detected anti-xa
assay apixaban
infusion monitored
monitored assay
apixaban detected
showing lack
study detectable
detectable apixaban
long apixaban
included study

Similar Publications

Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.

Am J Health Syst Pharm 2020 08;77(Suppl 3):S59-S65

Department of Pharmaceutical Services, Sanford USD Medical Center, Sioux Falls, SD.

Purpose: To determine a patient's clinical course based on the use of an activated partial thromboplastin time (aPTT) or heparin anti-Xa assay when transitioning from rivaroxaban or apixaban to an unfractionated heparin infusion.

Methods: A retrospective chart review was conducted to investigate how unfractionated heparin infusions were managed at a tertiary care hospital in the setting of recent apixaban or rivaroxaban administration. Patients were separated into 2 cohorts based on the chosen heparin infusion monitoring assay: heparin anti-Xa or aPTT. Read More

View Article and Full-Text PDF
August 2020

An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.

Int J Lab Hematol 2019 Jun 30;41(3):309-315. Epub 2019 Jan 30.

Arianna Anticoagulazione Foundation, Bologna, Italy.

Introduction: Co-administration of enoxaparin and a direct oral factor Xa inhibitor (xabans: apixaban, edoxaban, rivaroxaban) could give rise to the problem of overlapping the anti-Xa activity when measuring direct oral anticoagulant (DOAC) levels. We aimed to evaluate in vitro the degree of the interference of increasing enoxaparin concentrations on xaban plasma levels measured by different chromogenic anti-Xa assays with drug-specific calibrators and controls.

Methods: Seven plasma samples were spiked with apixaban, edoxaban, or rivaroxaban at fixed concentration, and enoxaparin at increasing concentrations (0, 0. Read More

View Article and Full-Text PDF
June 2019

Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors.

J Thromb Haemost 2020 07 4;18(7):1653-1660. Epub 2020 May 4.

Special Coagulation Laboratory, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Background: Direct factor Xa (FXa) inhibitors are increasingly prescribed for outpatients, and those transitioning to unfractionated heparin (UFH) for hospital admission are monitored via an anti-FXa assay. Because of assay interference, UFH results would often be critically elevated, confounding dosing.

Objectives: An anti-factor IIa (FIIa) UFH assay was evaluated for clinical use. Read More

View Article and Full-Text PDF
July 2020

Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.

Am J Health Syst Pharm 2019 Apr;76(8):505-511

Sanford USD Medical Center, Sioux Falls, SD, and University of South Dakota Sanford School of Medicine, Sioux Falls, SD.

Purpose: This case series presents 3 patients with acute kidney injury taking apixaban or rivaroxaban and transitioning to a heparin infusion.

Summary: Case 1 was a 78-year-old man admitted with respiratory failure, acute decompensated heart failure, and acute kidney injury. He was taking apixaban for atrial flutter. Read More

View Article and Full-Text PDF
April 2019